SQZ Biotechnologies (NYSE:SQZ) Announces Quarterly Earnings Results

SQZ Biotechnologies (NYSE:SQZ – Get Rating) posted its quarterly earnings data on Thursday. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.01), Fidelity Earnings reports. SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%.

SQZ Biotechnologies Stock Up 4.6 %

NYSE:SQZ opened at $3.39 on Friday. SQZ Biotechnologies has a twelve month low of $2.61 and a twelve month high of $16.17. The company has a market cap of $95.43 million, a P/E ratio of -1.28 and a beta of 2.65. The business has a 50 day moving average price of $3.25 and a two-hundred day moving average price of $4.31.

Insider Activity at SQZ Biotechnologies

In other news, Director Klavs F. Jensen acquired 14,326 shares of the stock in a transaction on Wednesday, May 25th. The shares were purchased at an average price of $3.52 per share, for a total transaction of $50,427.52. Following the transaction, the director now directly owns 353,309 shares of the company’s stock, valued at $1,243,647.68. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 18.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On SQZ Biotechnologies

A hedge fund recently raised its stake in SQZ Biotechnologies stock. Charles Schwab Investment Management Inc. boosted its holdings in SQZ Biotechnologies (NYSE:SQZ – Get Rating) by 7.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 60,693 shares of the company’s stock after purchasing an additional 4,196 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.22% of SQZ Biotechnologies worth $292,000 at the end of the most recent quarter. 66.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital started coverage on shares of SQZ Biotechnologies in a research report on Wednesday, May 25th. They issued a “buy” rating and a $17.00 price target on the stock.

About SQZ Biotechnologies

(Get Rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.